All
2 July 2025
MaaT Pharma Announces Exclusive Commercialization Partnership With Clinigen for Xervyteg® in acute Graft-versus Host Disease in Europe
MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated...
23 June 2025
Enterome presents positive Phase 2 interim results in relapsed/refractory indolent non-Hodgkin lymphoma after EO2463 OncoMimics™ immunotherapy treatment at ICML
60% (12/20) complete response rate after treatment with EO2463 in combination with lenalidomide and rituximab (R2).
EO2463 plus R2 was well tolerated in patients with...
13 June 2025
MaaT Pharma Presents Updated Positive Data in Early Access Program for Xervyteg® at the EHA Congress
The Company, a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with...
13 June 2025
The top 50 venture investors in France : Seventure ranked as #7
We mined CB Insights data on top France-based firms to rank them based on their portfolio strength and ability to predict future winners.
12 June 2025
Enterome, raises $19 million to fund clinical development of its OncoMimics™ immunotherapies to treat Follicular Lymphoma
Enterome, a clinical-stage company developing first-in-class OncoMimics™ immunotherapies to treat cancer, has raised $19 million in a new private financing.
2 June 2025
Enterome to present positive Phase 2 indolent non-Hodgkin lymphoma data for its OncoMimics™ EO2463 at ICML
Enterome SA, a clinical-stage company developing first-in-class OncoMimics™ immunotherapies to treat cancer, will present positive data from its Phase 1/2 clinical study with...
30 May 2025
Enterome presents positive Phase 1/2 MSS/pMMR metastatic colorectal cancer data in patients treated with EO4010 OncoMimics™ immunotherapy plus nivolumab at ASCO 2025
Enterome SA, a clinical-stage company developing first-in-class OncoMimics™ immunotherapies to treat cancer, announces it will present new positive data from its ongoing...
23 April 2025
Animab Secures EUR 10 Million in Series B Financing to Launch Nanoprotec® in Europe and Expand Pipeline
•All current investors participated in the round led by AIF,PMV and QBIC III, alongside new investor Anacura.
•Funds will support EU commercialization of...